Literature DB >> 11675421

Acceleration of neutrophil apoptosis by glucose-containing peritoneal dialysis solutions: role of caspases.

Marina Penélope Catalan1, Ana Reyero1, Jesús Egido1, Alberto Ortiz1.   

Abstract

Commercial, glucose-containing peritoneal dialysis (PD) solutions have deleterious effects on leukocytes and mesothelial cells that contribute to an impaired peritoneal defense. However, the molecular mechanisms of these deleterious effects are poorly understood. The effect of PD solutions on neutrophil viability, the molecular mechanisms of cell death, its functional consequences, and the possibilities for pharmacologic modulation have now been studied. The effect of newly available, bicarbonate-buffered PD solutions were further investigated. Lactate-buffered, glucose-containing PD solutions increased the apoptosis rate of cultured neutrophils (control media versus 4.25% glucose PD solution: 31 +/- 3% versus 52 +/- 3% apoptosis at 24 h, P < 0.001). Bicarbonate-buffered, 4.25% glucose-containing PD solutions with low concentration of glucose degradation products did not increase the rate of apoptosis. Apoptosis induced by lactate-buffered, 4.25% glucose PD solutions was not related to hyperosmolality or acidic pH and was not reproduced by increasing the glucose concentration by the addition of glucose to a commercial, lactate-buffered fluid. Neutrophil apoptosis was associated with caspase-3 activation. Inhibition of caspase-3 by the use of the caspase-3 inhibitor acetyl-Asp-Glu-Val-Asp-fmk or the broad-spectrum caspase inhibitor benzyloxycarbonyl-Val-Ala-DL-Asp-fluoromethylketone (zVAD-fmk) prevented features of apoptosis, such as morphologic changes, internucleosomal DNA degradation, and the appearance of hypodiploid cells and increased the number of viable, trypan blue-excluding neutrophils. Furthermore, zVAD-fmk increased neutrophil phagocytosis of bacteria. However, the caspase-1 inhibitor acetyl-Tyr-Val-Ala-Asp-aldehyde did not prevent cell death. These data suggest that unidentified components in commercial, lactate-buffered, high-glucose PD fluid accelerate the rate of neutrophil apoptosis. Glucose degradation products may be such unidentified components. Acceleration of neutrophil apoptosis may contribute to the impaired local defense system of patients undergoing PD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11675421     DOI: 10.1681/ASN.V12112442

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  5 in total

Review 1.  An update on peritoneal dialysis solutions.

Authors:  Elvia García-López; Bengt Lindholm; Simon Davies
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

2.  BASP1 promotes apoptosis in diabetic nephropathy.

Authors:  Maria Dolores Sanchez-Niño; Ana Belen Sanz; Corina Lorz; Andrea Gnirke; Maria Pia Rastaldi; Viji Nair; Jesus Egido; Marta Ruiz-Ortega; Matthias Kretzler; Alberto Ortiz
Journal:  J Am Soc Nephrol       Date:  2010-01-28       Impact factor: 10.121

3.  Peritoneal Cell-free DNA: an innovative method for determining acute cell damage in peritoneal membrane and for monitoring the recovery process after peritonitis.

Authors:  Grazia Maria Virzì; Sabrina Milan Manani; Alessandra Brocca; Vincenzo Cantaluppi; Massimo de Cal; Silvia Pastori; Ilaria Tantillo; Roberto Zambon; Carlo Crepaldi; Claudio Ronco
Journal:  J Nephrol       Date:  2015-05-27       Impact factor: 3.902

4.  Healthcare-associated infections: new challenges looking for answers.

Authors:  Jaime Esteban; Alberto Ortiz; Ricardo Fernández-Roblas
Journal:  Clin Kidney J       Date:  2015-01-28

5.  A nanoconjugate Apaf-1 inhibitor protects mesothelial cells from cytokine-induced injury.

Authors:  Beatriz Santamaría; Alberto Benito-Martin; Alvaro Conrado Ucero; Luiz Stark Aroeira; Ana Reyero; María Jesús Vicent; Mar Orzáez; Angel Celdrán; Jaime Esteban; Rafael Selgas; Marta Ruíz-Ortega; Manuel López Cabrera; Jesús Egido; Enrique Pérez-Payá; Alberto Ortiz
Journal:  PLoS One       Date:  2009-08-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.